Obesity Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Novo Nordisk, Boehringer Ingelheim, Pfizer, BioAge Labs, Aphaia Pharma, Neothetics, NovMetaPharma, Carmot

The Obesity Market Forecast-2034 report offers an in-depth understanding of the Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the 7MM.
DelveInsight's "Obesity Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Obesity, offering comprehensive insights into the Obesity revenue trends, prevalence, and treatment landscape. The report delves into key Obesity statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Obesity therapies. Additionally, we cover the landscape of Obesity clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Obesity treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Obesity space.

To Know in detail about the Obesity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obesity Market Forecast [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Obesity Market Report:

*
The Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
Key Obesity Companies: Novo Nordisk, Boehringer Ingelhium, Pfizer, BioAge Labs, Aphaia Pharma US LLC, Neothetics, Inc, NovMetaPharma Co., Ltd, Carmot Therapeutics, Inc., Aardvark Therapeutics, Inc., Glyscend, Inc., Palatin Technologies, Inc, Regor Pharmaceuticals Inc., and others

*
Key Obesity Therapies: Oral semaglutide, Survodutide (BI 456906), Danuglipron (PF-06882961), Azelaprag (BGE-105), APHD-012, LIPO-102, Cyclo-Z, CT-868, ARD-101, GLY-200, Bremelanotide, RGT001-075, and others

*
The Obesity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obesity pipeline products will significantly revolutionize the Obesity market dynamics.

*
In June 2024, Researchers at the Children's Hospital of Philadelphia (CHOP) have uncovered how a molecule regulates insulin sensitivity, which could lead to new therapeutic targets for type 2 diabetes related to obesity.

*
In June 2024, In the first quarter of 2024, Novo Nordisk and Eli Lilly led the obesity market, with Novo Nordisk earning $6.3 billion and Eli Lilly $2.3 billion in sales from their weight-loss medications.

*
In June 2024, The US House Ways and Means Committee has suggested a plan for Medicare to include coverage for GLP-1 weight-loss medications such as Wegovy and Zepbound.

*
In June 2024, Zealand Pharma has announced a share issuance to raise DKK 7 billion ($1 billion) to support the development of its obesity treatment candidates.

*
In June 2024, Form Health secured $38 million in a Series B funding round to advance its evidence-based obesity care programs and improve its telehealth platform.

*
In June 2024, Novo Nordisk revealed a $4.1 billion investment to construct a new factory in North Carolina, aiming to boost production of Wegovy and Ozempic.

*
In June 2024, Researchers discovered that the decrease in coronary heart disease rates among individuals under 60 in the UK has plateaued, likely due to increasing obesity rates.

*
In June 2024, At the ADA's 84th Scientific Sessions, three studies highlighted new developments in drug therapies for obesity, including findings on GLP-1 receptor agonists.

*
In June 2024, Palatin Technologies, a biopharmaceutical firm focused on pioneering treatments that target the melanocortin receptor system, has launched a Phase II clinical study of bremelanotide for obesity treatment. Approved by the FDA, the trial will evaluate the effectiveness, safety, and tolerability of bremelanotide when used in conjunction with tirzepatide, a GLP-1/GIP therapy, in patients with obesity.

*
In 2023, the total number of prevalent obesity cases in the United States was approximately 114 million. According to DelveInsight's estimates, this number is projected to rise by 2034.

*
In the United States, the treatment rate for children with obesity was lower compared to adults, with an estimated 6,000 children receiving treatment for obesity in 2023.

*
In 2023, approximately 360,000 adults with obesity received treatment, and this number is projected to grow by 2034.

*
In 2023, there were approximately 2,500,000 cases of obesity across the EU4 countries and the UK, with Germany reporting the highest number of cases.

Obesity Overview

Obesity is a medical condition characterized by excessive accumulation of body fat that can negatively impact health. It is typically measured using the Body Mass Index (BMI), where a BMI of 30 or higher indicates obesity. Obesity can lead to various health problems, including heart disease, diabetes, and high blood pressure. It is often influenced by a combination of genetic, behavioral, and environmental factors, including poor diet, lack of physical activity, and hormonal imbalances.

Get a Free sample for the Obesity Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market [https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Obesity Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Obesity Epidemiology Segmentation:

The Obesity market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalent Cases of Obesity in the 7MM

*
Total Obesity patients seeking help in the 7MM

*
Total Treated Cases of Obesity in the 7MM

Download the report to understand which factors are driving Obesity epidemiology trends @ Obesity Epidemiology Forecast [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Obesity Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obesity market or expected to get launched during the study period. The analysis covers Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Obesity Therapies and Key Companies

*
Oral semaglutide : Novo Nordisk

*
Survodutide (BI 456906): Boehringer Ingelhium

*
Danuglipron (PF-06882961): Pfizer

*
Azelaprag (BGE-105): BioAge Labs

*
APHD-012: Aphaia Pharma US LLC

*
LIPO-102: Neothetics, Inc

*
Cyclo-Z: NovMetaPharma Co., Ltd

*
CT-868: Carmot Therapeutics, Inc.

*
ARD-101: Aardvark Therapeutics, Inc.

*
GLY-200: Glyscend, Inc.

*
Bremelanotide: Palatin Technologies, Inc

*
RGT001-075: Regor Pharmaceuticals Inc.

Discover more about therapies set to grab major Obesity market share @ Obesity Treatment Landscape [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Obesity Market Strengths

*
There has been an increase in pharmaceutical companies' investment in the research and development of drugs.

*
New and emerging mobile technologies are providing unprecedented possibilities for understanding and intervening in obesity

Obesity Market Opportunities

*
Several key pharmaceutical players such as Novo Nordisk, Eli Lilly and Company, and others have taken the initiative to meet the unmet needs of the obesity market's present situation.

*
Many government and nongovernment bodies are trying to make the patients aware of obesity. This will expand the market further as such patients will seek appropriate treatment.

Scope of the Obesity Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Obesity Companies: Novo Nordisk, Boehringer Ingelhium, Pfizer, BioAge Labs, Aphaia Pharma US LLC, Neothetics, Inc, NovMetaPharma Co., Ltd, Carmot Therapeutics, Inc., Aardvark Therapeutics, Inc., Glyscend, Inc., Palatin Technologies, Inc, Regor Pharmaceuticals Inc., and others

*
Key Obesity Therapies: Oral semaglutide, Survodutide (BI 456906), Danuglipron (PF-06882961), Azelaprag (BGE-105), APHD-012, LIPO-102, Cyclo-Z, CT-868, ARD-101, GLY-200, Bremelanotide, RGT001-075, and others

*
Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies

*
Obesity Market Dynamics: Obesity market drivers and Obesity market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Obesity Unmet Needs, KOL's views, Analyst's views, Obesity Market Access and Reimbursement

To know more about Obesity companies working in the treatment market, visit @ Obesity Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Obesity Market Report Introduction

2. Executive Summary for Obesity

3. SWOT analysis of Obesity

4. Obesity Patient Share (%) Overview at a Glance

5. Obesity Market Overview at a Glance

6. Obesity Disease Background and Overview

7. Obesity Epidemiology and Patient Population

8. Country-Specific Patient Population of Obesity

9. Obesity Current Treatment and Medical Practices

10. Obesity Unmet Needs

11. Obesity Emerging Therapies

12. Obesity Market Outlook

13. Country-Wise Obesity Market Analysis (2020-2034)

14. Obesity Market Access and Reimbursement of Therapies

15. Obesity Market Drivers

16. Obesity Market Barriers

17. Obesity Appendix

18. Obesity Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=obesity-market-to-show-remarkable-growth-trends-from-2024-to-2034-delveinsight-reports-novo-nordisk-boehringer-ingelheim-pfizer-bioage-labs-aphaia-pharma-neothetics-novmetapharma-carmot]
Phone: +14699457679
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services



This release was published on openPR.